TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02846454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inulin
Description: Investigate the satiating effects of consuming 4g/d inulin in 2 daily doses of 2g

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arabinoxylan
Description: Investigate the satiating effects of consuming 4g/d arabinoxylan in 2 daily doses of 2g
Study: NCT03420963

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord Blood-derived Expanded Allogeneic Natural Killer Cells
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study: NCT03828669

Intervention type: BEHAVIORAL
Intervention: Recovery Toolkits
Description: Recovery Toolkits are presented to patients in a branded bag and include a brochure, a self-help behavioral pain medicine book, a downloadable app, earbuds, and access to digital behavioral medicine (the My Surgical Success program including online educational videos)
Study: NCT00305682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: Mycophenolate mofetil (MMF) 3 gram/day for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: Mycophenolate mofetil (MMF) 3 gram/day for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: umbilical cord blood transplantation
Description: One or 2 UCB units may be infused to achieve the required cell dose.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: umbilical cord blood transplantation
Description: One or 2 UCB units may be infused to achieve the required cell dose.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: umbilical cord blood transplantation
Description: One or 2 UCB units may be infused to achieve the required cell dose.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: umbilical cord blood transplantation
Description: One or 2 UCB units may be infused to achieve the required cell dose.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: umbilical cord blood transplantation
Description: One or 2 UCB units may be infused to achieve the required cell dose.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: umbilical cord blood transplantation
Description: One or 2 UCB units may be infused to achieve the required cell dose.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: total body irradiation
Description: Administered Day -1, 200 cGy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: total body irradiation
Description: Administered Day -1, 200 cGy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: total body irradiation
Description: Administered Day -1, 200 cGy
Study: NCT01741545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study: NCT02792816

Intervention type: DRUG
Intervention: First line antimalarial in Myanmar (artemether-lumefrantrine, dihydroartemisinin-piperaquine, and artesunate-mefloquine)
Description: Being a observational cohort study, one of the ACT was selected in each study site to assess the efficacy and safety.

Intervention type: DRUG
Intervention: First line antimalarial in Myanmar (artemether-lumefrantrine, dihydroartemisinin-piperaquine, and artesunate-mefloquine)
Description: Being a observational cohort study, one of the ACT was selected in each study site to assess the efficacy and safety.

Intervention type: DRUG
Intervention: First line antimalarial in Myanmar (artemether-lumefrantrine, dihydroartemisinin-piperaquine, and artesunate-mefloquine)
Description: Being a observational cohort study, one of the ACT was selected in each study site to assess the efficacy and safety.

Intervention type: DRUG
Intervention: First line antimalarial in Myanmar (artemether-lumefrantrine, dihydroartemisinin-piperaquine, and artesunate-mefloquine)
Description: Being a observational cohort study, one of the ACT was selected in each study site to assess the efficacy and safety.

Intervention type: DRUG
Intervention: First line antimalarial in Myanmar (artemether-lumefrantrine, dihydroartemisinin-piperaquine, and artesunate-mefloquine)
Description: Being a observational cohort study, one of the ACT was selected in each study site to assess the efficacy and safety.

Intervention type: DRUG
Intervention: First line antimalarial in Myanmar (artemether-lumefrantrine, dihydroartemisinin-piperaquine, and artesunate-mefloquine)
Description: Being a observational cohort study, one of the ACT was selected in each study site to assess the efficacy and safety.
Study: NCT02570828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Imaging
Description: FLIR ONE attachment to an iPhone
Study: NCT03499665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PNF, Myofascial Releasing Maneuvers, Home Exercise Group
Description: For Group 1 (n:20), the PNF, myofascial releasing and home exercises were used to decrease pain, jaw restriction and improve functional mobility on the masseter, lateral and medial pterygoid, buccinator, temporalis, orbicularis oris, orbicularis oculi, upper side of trapezius muscle, splenius, scalenous, and cervical extensor muscle in 20 patients with bruxism, for 2 and 6 weeks after pre-evaluation. PNF, myofascial releasing and home exercises were administered for 2 weeks, followed by 3 sets of 10 repeat home exercises and 6 weeks under physiotherapist control.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Releasing Maneuvers and Home Exercises Group
Description: In Group 2 (n:15), as myofascial releasing and home exercise group,final evaluation was made with 10 sets of myofascial releasing and home exercises for 2 and 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: In Group 3 (n:17), as the control group, no myofascial releasing or Proprioceptive Neuromuscular Facilitation exercises were applied.
Study: NCT02559843

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pomegranate juice

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle modification
Study: NCT02749695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melsmon
Description: Placental extract Melsmon® (Japan): 2 ml (100 mg), subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 ml subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
Study: NCT03694197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praluent
Description: Subcutaneous (SC) administration
Study: NCT00996697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/formoterol and tiotropium
Description: Symbicort 200/2, 2puff bid plus tiotropium 18mcg/day
Study: NCT02555358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel,0xaliplatin,capecitabine
Description: docetaxel 60mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14; oxaliplatin 130mg/m2， ivgtt，2h，d1;q21d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin,capecitabine
Description: oxaliplatin 130mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14;q21d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin,capecitabine
Description: oxaliplatin 130mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14;q21d
Study: NCT01215162

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intra-operative radiation to tumor bed
Description: IOERT is given to the tumor bed. Applicator selection should allow treatment of the tumor bed plus 1-2 cm margin. The surgical incision may need to be enlarged slightly to allow the placement of the appropriate applicator. The use of more than 1 treatment field is discouraged. In order to encompass the entire tumor bed in 1 treatment field, it may be necessary to suture the mammary parenchyma loosely so that the lateral margins of the tumor bed are brought into apposition. Electron energy used for the treatment. If the tumor bed can be flattened and encompassed by an applicator, 6 MeV electron is recommended. Use of bolus material may be considered to increase the surface dose. If the mammary parenchyma has been brought into apposition by sutures, a higher electron energy may be necessary to allow adequate dose coverage to a depth of 1.0-2.0 cm into the tumor bed. The dose of IOERT is 1000 cGy, prescribed to the 90% isodose line.
Study: NCT03167424

Intervention type: DEVICE
Intervention: Treatment of restenosis
Description: Treatment of in-stent restenosis
Study: NCT01718106

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implantation of a bioabsorbable polymer DES
Description: implantation in patients with long coronary artery stenosis of a single long or two shorter overlapped bioabsorbable polymer DES

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implantation of a bioabsorbable polymer DES
Description: implantation in patients with long coronary artery stenosis of a single long or two shorter overlapped bioabsorbable polymer DES
Study: NCT03173508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Study: NCT03615430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: serratus plane block with local anesthetic
Description: The high-frequency linear array ultrasound transducer (UST) was placed parallel to the cephalocaudal axis of the body in T4 levels on the side of the mid-axillary line, identifying latissimus dorsi and serratus anterior, through the thoracic artery to help to find the serratus anterior and 15 ml 0.25% ropivacaine was administered.
Study: NCT03285113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GiMer Medical MN 1000 External Stimulator
Description: Trial stimulator to generate pulsed ultrahigh frequency (\>200KHz) electrical stimulation, delivered via lead around DRG, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
Study: NCT00508339

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Toronto Extremity Salvage Score (TESS) questionnaire.
Study: NCT03615430

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: serratus plane block with saline
Description: The high-frequency linear array ultrasound transducer (UST) was placed parallel to the cephalocaudal axis of the body in T4 levels on the side of the mid-axillary line, identifying latissimus dorsi and serratus anterior, through the thoracic artery to help to find the serratus anterior and 15 ml saline was administered.
Study: NCT00996697

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide/formoterol and placebo
Description: Symbicort 200/6 2puff bid and placebo
Study: NCT02438735

Intervention type: PROCEDURE
Intervention: laparoscopic endometrioma excision

Intervention type: OTHER
Intervention: Conservative follow up

Intervention type: OTHER
Intervention: Conservative follow up
Study: NCT03198663

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: POSSE
Description: Popular-opinion leader

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POSSE
Description: Popular-opinion leader
Study: NCT03774329

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Patients included in the control group will not benefit from the intervention in adapted physical activity. However, this will not affect their support. Patients will be seen by their specialist doctor as part of the usual management of their IBD.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adapted physical activity
Description: Patients in the experimental group will have, in addition to their usual follow-up with their specialist doctor, an intervention in adapted physical activity at home, at the rate of 3 sessions (of a duration of 10 to 20 minutes) per week during 9 consecutive months.
Study: NCT01140438

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin+ NPH insulin
Description: Metformin 500 mg + 500 mg + 1000 mg NPH insulin , initially 0.20 U/kg body weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin + sitagliptin +/- repaglinide
Description: Metformin 500 mg + 500 mg + 1000 mg Sitagliptin 100 mg x 1 Repaglinide 1 mg x 3
Study: NCT04580784

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Weekly hypofractionation for early breast cancer
Description: Testing the feasibility of a hypofractionated adjuvant radiotherapy regimen after breast surgery on a-once-weekly basis for a total dose of 28.5Gy in 5 fractions over 5 weeks
Study: NCT03097445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: mailed 5-week course of Habitrol® transdermal nicotine patches
Study: NCT02871076

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: Patients will be randomized to either treatment arm, verum acupuncture or sham placebo acupuncture.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients will be randomized to either treatment arm, verum acupuncture or sham placebo acupuncture.
Study: NCT03724890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814
Description: Participants will receive M3814 twice daily (BID) continuously starting from Day 1 until progressive disease (PD) or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814
Description: Participants will receive M3814 twice daily (BID) continuously starting from Day 1 until progressive disease (PD) or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814
Description: Participants will receive M3814 concomitantly with RT once (QD) daily starting Day 1 for 5 days per week for 2 weeks in total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants will receive avelumab once every 2 weeks (Q2W) starting from Day 1 until PD or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants will receive avelumab once every 2 weeks (Q2W) starting from Day 1 until PD or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants will receive avelumab once every 2 weeks (Q2W) starting from Day 1 until PD or unacceptable toxicity.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Participants will receive radiotherapy at the dose of 3 grays (Gy) per day starting Day 1 for 5 days per week for 2 weeks.
Study: NCT01751087

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: oral mifepristone 200 mg on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: buccal misoprostol 400 mcg on Day 2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osmotic dilators
Description: osmotic dilators on Day 1

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osmotic dilators
Description: osmotic dilators on Day 1

Intervention type: DEVICE
Group type: OTHER
Intervention: Osmotic dilators
Description: osmotic dilators on Day 1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo for mifepristone, on day 1

Intervention type: OTHER
Group type: OTHER
Intervention: placebo
Description: placebo for mifepristone, on day 1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo for misoprostol, on day 2

Intervention type: OTHER
Group type: OTHER
Intervention: placebo
Description: placebo for misoprostol, on day 2
Study: NCT03648580

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Complete powder
Description: Supply the Ensure Complete powder that will be the oral nutrition supplement, with the dose of 6 scoops (53.8 grams) twice daily.Duration: 12 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: verbal nutrition education
Description: give the verbal nutrition education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: verbal nutrition education
Description: give the verbal nutrition education
Study: NCT02484807

Intervention type: OTHER
Intervention: no intervention, only observation of different groups

Intervention type: OTHER
Intervention: no intervention, only observation of different groups

Intervention type: OTHER
Intervention: no intervention, only observation of different groups

Intervention type: OTHER
Intervention: no intervention, only observation of different groups

Intervention type: OTHER
Intervention: no intervention, only observation of different groups

Intervention type: OTHER
Intervention: no intervention, only observation of different groups
Study: NCT03895879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab sc (162 mg) once every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Tocilizumab sc (162 mg) once every week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Tocilizumab sc (162 mg) once every week
Study: NCT04334863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WP1066
Description: WP1066 is an analogue of caffeic acid that is a potent inhibitor of p-STAT3.~It will be taken by mouth 2 times per day on Monday, Wednesday, and Friday of Weeks 1 and 2 of each 28-day cycle.
Study: NCT01277835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Infusion
Description: Infusion of lidocaine 3mg/min or 2mg/min during surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline Infusion at same rate as experimental arm
Study: NCT02349763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Dexamethasone
Description: Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Dexamethasone
Description: Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
Study: NCT02643407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 60mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: 80mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75mg/m2
Study: NCT02031250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 40mg/m2 administered as an IV infusion prior to radiotherapy on day 1 of each week of chemo-irradiation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 40mg/m2 administered as an IV infusion prior to radiotherapy on day 1 of each week of chemo-irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patients considered medically unfit to receive Cisplatin as determined by the prescribing physician, will receive Carboplatin via IV infusion on day 1 of each week of chemo-irradiation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Patients considered medically unfit to receive Cisplatin as determined by the prescribing physician, will receive Carboplatin via IV infusion on day 1 of each week of chemo-irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT (Intensity-Modulated Radiation Therapy)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT (Intensity-Modulated Radiation Therapy)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boost Radiation to Hypoperfused Volumes
Study: NCT02469363

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: Hemodynamic parameters after endotracheal intubation with Classic laryngoscope (Macintosh)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mc-Coy laryngoscope
Description: Hemodynamic parameters after endotracheal intubation with Mc-Coy laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-Mac videolaryngoscope
Description: Hemodynamic parameters after endotracheal intubation with C-Mac videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath videolaryngoscope
Description: Hemodynamic parameters after endotracheal intubation with McGrath videolaryngoscope
Study: NCT02220049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study: NCT03993535

Intervention type: DRUG
Group type: OTHER
Intervention: selective serotonin reuptake inhibitor
Description: open treatment based on patient preference and treatment availability
Study: NCT02943538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Monitoring and control is performed through telematics platform integrated management of chronic NOMHAD, configurated to respond the patients specific needs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telephone
Description: A telephone control of their state and evolution will be made through the nursing staff of the unit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care
Description: Conventional care provided in the unit to patients with IBD -high moderate complexity.
Study: NCT00922896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Cisplatin, Erlotinib (Tarceva)
Description: * Erlotinib 100 mg po q d daily AND~* Gemcitabine 1000 mg/m² with 250 mL of normal saline intravenously infusion over 30 mins on Day 1, 8~* Cisplatin 25 mg/m2 with 150 mL of normal saline intravenously infusion over 60 mins on D1,8~Every 3 weeks